247092-10-0

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
METHYL 2-CHLORO-5-HYDROXYBENZOATE is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals, contributing to the development of new drugs and pesticides.
Used in Cosmetic and Personal Care Products:
METHYL 2-CHLORO-5-HYDROXYBENZOATE is used as a preservative for its ability to inhibit microbial growth, ensuring the safety and shelf life of cosmetic and personal care products.
Used in Antimicrobial Applications:
METHYL 2-CHLORO-5-HYDROXYBENZOATE is used as an antimicrobial agent for its effectiveness in inhibiting the growth of certain bacteria and fungi, providing a protective measure against microbial contamination in various products.
Used in Antioxidant Applications:
Leveraging its antioxidant properties, METHYL 2-CHLORO-5-HYDROXYBENZOATE is used to prevent oxidation in products, thereby maintaining product quality and extending shelf life.

InChI:InChI=1/C8H7ClO3/c1-12-8(11)6-4-5(10)2-3-7(6)9/h2-4,10H,1H3

Upstream product

• 19438-10-9 methyl 3-hydroxybenzoate 
• 89-54-3 2-chloro-5-aminobenzoic acid 
• 67-56-1 methanol 
• 56961-30-9 2-chloro-5-hydroxybenzoic acid 

Downstream Products

• 312313-04-5 2-chloro-5-hydroxybenzamide 
• 1143025-99-3 (S)-tert-butyl 3-(3-carbamoyl-4-chlorophenoxy)pyrrolidine-1-carboxylate 
• 1394349-06-4 2-chloro-5-dimethylthiocarbamoyloxy-benzoic acid methyl ester 
• 17642-17-0 2-chloro-5-mercapto-benzoic acid 
• 1394349-07-5 2-chloro-5-dimethylcarbamoylsulfanyl-benzoic acid methyl ester 
• 1417411-59-6 C₁₁H₁₅ClN₂O₂ 
• 1394349-08-6 2-chloro-5-(pyridin-2-ylsulfanyl)benzoic acid 
• 1394349-12-2 2-chloro-5-(2-chloropyrimidin-4-ylsulfanyl)benzoic acid 
• 1394349-16-6 2-chloro-5-[2-(2-trimethylsilanyl-ethoxy)-pyrimidin-4-ylsulfanyl]-benzoic acid 
• 1394349-19-9 2-chloro-5-(2-methoxy-pyrimidin-4-ylsulfanyl)-benzoic acid 
• 1422205-90-0 2-chloro-5-(2,2-difluoroethoxy)benzoic acid 
• 1403782-72-8 2-chloro-5-(4,4,4-trifluorobutoxy)benzoic acid 
• 1001026-31-8 ethyl 6-{4-[allyl(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-2-(2,2-difluoroethoxy)nicotinate 
• 1422205-91-1 methyl 2-chloro-5-(2,2-difluoroethoxy)benzoate 

Relevant academic research and scientific papers

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

Rapid Access to Orthogonally Functionalized Naphthalenes: Application to the Total Synthesis of the Anticancer Agent Chartarin

We report the synthesis of orthogonally functionalized naphthalenes from simple, commercially available indanones in four steps. The developed method proceeds through a two-step process that features a thermally induced fragmentation of a cyclopropane indanone with simultaneous 1,2-chloride shift. Migration of the chloride substituent occurs in a regioselective manner to preferentially afford the para-chloronaphthol substitution pattern. The obtained naphthols are versatile building blocks that can be selectively modified and used for the efficient construction of biologically active molecules. This has enabled the total synthesis of the potent anticancer natural product chartarin through a highly convergent retrosynthetic bond disconnection.

Synthesis, structure-activity relationships, and biological evaluation of a series of benzamides as potential multireceptor antipsychotics

In the present study, a series of benzamides, endowed with potent dopamine D2, serotonin 5-HT1A and 5-HT2A receptors properties, was synthesized and evaluated as potential antipsychotics. Among them, 3-(4-(4-(6-fluorobenzo[d]isoxazol-3-yl)-piperidin-1-yl)butoxy)-N-methylbenzamide (21) and its fluoro-substituted analogue (22) held the best pharmacological binding profiles. They not only presented potent activities for D2, 5-HT1A, and 5-HT2A receptors, but were also endowed with low activities for 5-HT2C, H1 receptors and hERG channels, suggesting a low propensity of inducing weight gain and QT prolongation. In animal models, compounds 21 and 22 reduced phencyclidine-induced hyperactivity with a high threshold for catalepsy induction. It thus provides potential candidates for further preclinical studies.

The Catalyst-Controlled Regiodivergent Chlorination of Phenols

Different catalysts are demonstrated to overcome or augment a substrate's innate regioselectivity. Nagasawa's bis-thiourea catalyst was found to overcome the innate para-selectivity of electrophilic phenol chlorination, yielding ortho-chlorinated phenols that are not readily obtainable via canonical electrophilic chlorinations. Conversely, a phosphine sulfide derived from 2,2′-Bis(diphenylphosphino)-1,1′-binaphthyl (BINAP) was found to enhance the innate para-preference of phenol chlorination.

Design, synthesis and evaluation of second generation MurF inhibitors based on a cyanothiophene scaffold

MurF ligase is a crucial enzyme that catalyses the ultimate intracellular step of bacterial peptidoglycan biosynthesis, and thus represents an attractive target for antibacterial drug discovery. We designed, synthesized and evaluated a new series of cyanothiophene-based inhibitors of MurF enzymes from Streptococcus pneumoniae and Escherichia coli. The target compounds had increased polarity compared to the first generation of inhibitors, with demonstrated enzyme inhibitory potencies in the low micromolar range. Furthermore, the best inhibitors displayed promising antibacterial activities against selected Gram-positive and Gram-negative strains. These results represent an important step towards the development of new antibacterial agents targeting peptidoglycan biosynthesis.

BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to benzamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.

Structure-based design of a potent, selective, and brain penetrating PDE2 inhibitor with demonstrated target engagement

Structure-guided design led to the identification of the novel, potent, and selective phosphodiesterase 2 (PDE2) inhibitor 12. Compound 12 demonstrated a >210-fold selectivity versus PDE10 and PDE11 and was inactive against all other PDE family members up

BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS

The invention relates to benzamide derivatives of formula (I),wherein R1, R2, R3, R4, R5, R6, n and Y are as defined in the description, their preparation and their use as pharmaceutically active compounds.